Nkarta, Inc. (NASDAQ:NKTX) CEO Paul J. Hastings Sells 6,126 Shares of Stock

Nkarta, Inc. (NASDAQ:NKTXGet Rating) CEO Paul J. Hastings sold 6,126 shares of the business’s stock in a transaction dated Wednesday, September 21st. The stock was sold at an average price of $13.01, for a total value of $79,699.26. Following the completion of the sale, the chief executive officer now owns 274,335 shares in the company, valued at $3,569,098.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Nkarta Stock Performance

NKTX opened at $12.52 on Friday. The stock has a market cap of $609.22 million, a price-to-earnings ratio of -4.52 and a beta of 0.07. The stock’s 50 day moving average price is $14.58 and its 200-day moving average price is $13.36. Nkarta, Inc. has a one year low of $7.55 and a one year high of $31.45.

Nkarta (NASDAQ:NKTXGet Rating) last released its earnings results on Thursday, August 11th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.11. As a group, analysts predict that Nkarta, Inc. will post -2.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Parkwood LLC bought a new position in Nkarta in the second quarter worth approximately $31,000. Quantbot Technologies LP grew its stake in Nkarta by 39.1% in the first quarter. Quantbot Technologies LP now owns 3,200 shares of the company’s stock worth $36,000 after purchasing an additional 900 shares in the last quarter. Denali Advisors LLC bought a new position in Nkarta in the second quarter worth approximately $38,000. Federated Hermes Inc. grew its stake in Nkarta by 735.3% in the first quarter. Federated Hermes Inc. now owns 4,711 shares of the company’s stock worth $54,000 after purchasing an additional 4,147 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Nkarta in the second quarter worth approximately $131,000.

Analyst Ratings Changes

NKTX has been the topic of a number of research analyst reports. SVB Leerink initiated coverage on Nkarta in a research report on Monday, July 18th. They issued an “outperform” rating and a $30.00 target price on the stock. Needham & Company LLC assumed coverage on Nkarta in a research report on Thursday, July 28th. They set a “buy” rating and a $26.00 price objective on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Nkarta in a research report on Wednesday. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Nkarta currently has an average rating of “Buy” and an average price target of $39.63.

Nkarta Company Profile

(Get Rating)

Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.

See Also

Insider Buying and Selling by Quarter for Nkarta (NASDAQ:NKTX)

Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.